Read More

Symetryx Issues Open Letter To Shareholders In Regard To The Upcoming Annual General Meeting; Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & The Check-Cap Board Nominees, Recommends A Vote FOR The Symetryx Slate Of Director Candidat…

Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director CandidatesCites Unrealistic and Aggressive Valuation of

CHEK

Read More

Anaptys Expands Immune Cell Modulator Pipeline With Exclusive License To BDCA2 Modulator Antibody Portfolio From Centessa Pharmaceuticals; Anaptys Will Pay Centessa A One-Time Upfront Cash Payment Of $7M

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory

ANAB